APPLICATION OF PIMONIDAZOLE – MALIGNANT TISSUE

2. Tumors – Experimental

Brain

1. Bernsen HJ, Rijken PF, Peters JP, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 1999; 44: 129-36.
2. Bernsen HJ, Rijken PF, Peters H, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg 2000; 93: 449-54.
3. Olive PL, Durand RE, Raleigh JA, Luo C, Aquino-Parsons C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer 2000; 83: 1525-31.
4. Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA, van der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000; 48: 571-82.
5. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001; 61: 313-20.
6. Rijken PF, Peters JP, Van der Kogel AJ. Quantitative analysis of varying profiles of hypoxia in relation to functional vessels in different human glioma xenograft lines. Radiat Res 2002; 157: 626-32.
7. Sminia P, Acker H, Eikesdal HP, et al. Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma. Anticancer Res 2003; 23: 1461-6.
8. Zoula S, Rijken PF, Peters JP, et al. Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. Br J Cancer 2003; 88: 1439-44.
9. Cardenas-Navia LI, Yu D, Braun RD, Brizel DM, Secomb TW, Dewhirst MW. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res 2004; 64: 6010-7.
10. Kostourou V, Troy H, Murray JF, et al. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia 2004; 6: 401-11.
11. Post DE, Devi NS, Li Z, et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10: 8603-12.

12. Prabhakaran K, Sampson DA, Hoehner JC. Neuroblastoma survival and death: an in vitro model of hypoxia and metabolic stress. J Surg Res 2004; 116: 288-96.
13. Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther 2006; 13: 206-15.
14. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 2006; 20: E24.
15. Kang SH, Cho HT, Devi S, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 2006; 66: 11991-7.
16. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006; 47: 989-98.
17. Kumar S, Brown SL, Kolozsvary A, Freytag SO, Kim JH. Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells. J Neurooncol 2008.
18. Scigliano S, Pinel S, Poussier S, et al. Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and 18F-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts. Int J Oncol 2008; 32: 69-77.
19. Yeom CJ, Chung JK, Kang JH, et al. Visualization of Hypoxia-Inducible Factor-1 Transcriptional Activation in C6 Glioma Using Luciferase and Sodium Iodide Symporter Genes. J Nucl Med 2008.
20. Zhao D, Najbauer J, Garcia E, et al. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 2008; 6: 1819-29.

21. Zaghloul N, Hernandez SL, Bae JO, et al. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol 2009; 34: 401-7.
22. McGee MC, Hamner JB, Williams RF, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010; 76: 1537-45.
23. Foti R, Zucchelli S, Biagioli M, et al. Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. J Biol Chem 2010; 285: 18565-74.
24. Boult JK, Walker-Samuel S, Jamin Y, Leiper JM, Whitley GS, Robinson SP. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol 2011.
25. Burrell JS, Walker-Samuel S, Baker LC, et al. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. Int J Cancer 2012; 131: 1854-62.

26. Lemasson B, Christen T, Serduc R, et al. Evaluation of the Relationship between MR Estimates of Blood Oxygen Saturation and Hypoxia: Effect of an Antiangiogenic Treatment on a Gliosarcoma Model. Radiology 2012.

Breast

1. Samoszuk M, Corwin MA. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer 2003; 107: 159-63.
2. Franco M, Man S, Chen L, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006; 66: 3639-48.
3. Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther 2006; 13: 206-15.
4. Kirkpatrick JP, Hardee ME, Snyder SA, et al. The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 2006; 165: 192-201.
5. Lipnik K, Greco O, Scott S, et al. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology 2006; 349: 121-33.
6. Fang Y, Sullivan R, Graham CH. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 2007; 313: 867-77.
7. Karantza-Wadsworth V, Patel S, Kravchuk O, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007; 21: 1621-35.
8. Zhao D, Chang CH, Kim JG, Liu H, Mason RP. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome. Int J Radiat Oncol Biol Phys 2011; 80: 574-81.
9. Przybyla BD, Shafirstein G, Koonce NA, Webber JS, Griffin RJ. Conductive thermal ablation of 4T1 murine breast carcinoma reduces severe hypoxia in surviving tumour. Int J Hyperthermia 2012; 28: 156-62.
10. Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109: 2784-9.

Colorectal

1. Pedley RB, El-Emir Eb, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1524-31.

2. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004; 64: 6537-41.
3. Nelson DW, Cao H, Zhu Y, et al. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. Cancer Res 2005; 65: 6151-8.
4. Ceelen W, Smeets P, Backes W, et al. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys 2006; 64: 1188-96.
5. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007; 67: 7646-53.
6. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2007; 2: 119-25.
7. Shin KH, Diaz-Gonzalez JA, Russell J, et al. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 2007; 6: 70-5.
8. van der Bilt JD, Soeters ME, Duyverman AM, et al. Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol 2007; 170: 1379-88.
9. He F, Deng X, Wen B, et al. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res 2008; 68: 8597-606.
10. Kalber TL, Waterton JC, Griffiths JR, Ryan AJ, Robinson SP. Longitudinal in vivo susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude mice. J Magn Reson Imaging 2008; 28: 1451-8.
11. Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol 2008; 75: 627-38.
12. Ahlskog JK, Schliemann C, Marlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 2009; 101: 645-57.
13. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys 2009; 73: 1177-86.
14. Li XF, Sun X, Ma Y, et al. Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 2010; 37: 339-48.
15. Oehler C, O'Donoghue JA, Russell J, et al. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med 2011; 52: 437-44.
16. Vangestel C, Van de Wiele C, Van Damme N, et al. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by

irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med 2011; 52: 1786-94.

Gastric

1. Takahashi M, Yasui H, Ogura A, et al. X Irradiation Combined with TNF alpha-related Apoptosis-inducing Ligand (TRAIL) Reduces Hypoxic Regions of Human Gastric Adenocarcinoma Xenografts in SCID Mice. J Radiat Res (Tokyo) 2008; 49: 153-61.

Lung

1. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.
2. Huang G, Chen L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm 2009; 24: 589-96.
3. Oh M, Tanaka T, Kobayashi M, et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 2009; 36: 419-26.
4. Graves EE, Vilalta M, Cecic IK, et al. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 2010; 16: 4843-52.
5. Lee JC, Kinniry PA, Arguiri E, et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat Res 2010; 173: 590-601.

Melanoma

1. Lyng H, Sundfor K, Rofstad EK. Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiother Oncol 1997; 44: 163-9.
2. Rofstad EK, Maseide K. Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: acute and chronic hypoxia in individual tumours. Int J Radiat Biol 1999; 75: 1377-93.
3. Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 2000; 82: 1528-34.
4. Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002; 86: 301-8.

5. Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 2002; 62: 1847-53.
6. Rofstad EK, Tunheim SH, Mathiesen B, et al. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res 2002; 62: 661-4.
7. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 2004; 64: 13-8.
8. Liu J, Qu R, Ogura M, Shibata T, Harada H, Hiraoka M. Real-time Imaging of Hypoxia-inducible Factor-1 Activity in Tumor Xenografts. J Radiat Res (Tokyo) 2005; 46: 93-102.
9. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The Tumor Bed Effect: increased metastatic dissemination from hypoxia-Induced up-regulation of metastasis-promoting gene products. Cancer Res 2005; 65: 2387-96.
10. Stockwin LH, Blonder J, Bumke MA, et al. Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J Proteome Res 2006; 5: 2996-3007.
11. Rofstad EK, Galappathi K, Mathiesen B, Ruud EB. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007; 13: 1971-8.
12. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2007; 2: 119-25.
13. Gulliksrud K, Vestvik IK, Galappathi K, Mathiesen B, Rofstad EK. Detection of different hypoxic cell subpopulations in human melanoma xenografts by pimonidazole immunohistochemistry. Radiat Res 2008; 170: 638-50.
14. Gulliksrud K, Mathiesen B, Galappathi K, Rofstad EK. Quantitative assessment of hypoxia in melanoma xenografts by dynamic contrast-enhanced magnetic resonance imaging: intradermal versus intramuscular tumors. Radiother Oncol 2010; 97: 233-8.
15. Rofstad EK, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia 2010; 12: 889-98.
16. Simonsen TG, Gaustad JV, Rofstad EK. Development of hypoxia in a preclinical model of tumor micrometastases. Int J Radiat Oncol Biol Phys 2010; 76: 879-88.
17. Egeland TA, Gulliksrud K, Gaustad JV, Mathiesen B, Rofstad EK. Dynamic contrast-enhanced-MRI of tumor hypoxia. Magn Reson Med 2011.
18. Gulliksrud K, Ovrebo KM, Mathiesen B, Rofstad EK. Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic

contrast-enhanced magnetic resonance imaging. Radiother Oncol 2011; 98: 360-4.
19. Egeland TA, Gulliksrud K, Gaustad JV, Mathiesen B, Rofstad EK. Dynamic contrast-enhanced-MRI of tumor hypoxia. Magn Reson Med 2012; 67: 519-30.
20. Ellingsen C, Ovrebo KM, Galappathi K, Mathiesen B, Rofstad EK. pO(2) fluctuation pattern and cycling hypoxia in human cervical carcinoma and melanoma xenografts. Int J Radiat Oncol Biol Phys 2012; 83: 1317-23.
21. Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer 2012; 12: 388.
22. Ovrebo KM, Ellingsen C, Galappathi K, Rofstad EK. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts. Int J Radiat Oncol Biol Phys 2012; 83: e121-7.

Multiple Myeloma

1. Asosingh K, De Raeve H, de Ridder M, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005; 90: 810-7.
2. Hu J, Handisides DR, Van Valckenborgh E, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010; 116: 1524-7.

Non-small Cell Lung Carcinoma

1. McClelland MR, Carskadon SL, Zhao L, et al. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol 2007; 36: 343-50.
2. Graves EE, Vilalta M, Cecic IK, et al. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 2010; 16: 4843-52.
3. Huang T, Civelek AC, Li J, et al. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med 2012; 53: 1262-8.

Pancreatic Cancer

2. Okuda K, Okabe Y, Kadonosono T, et al. 2-Nitroimidazole-Tricarbocyanine Conjugate as a Near-Infrared Fluorescent Probe for in Vivo Imaging of Tumor Hypoxia. Bioconjugate Chem 2012; 23: 324-9.

Prostatic Cancer

1. Pollard M, Suckow MA. Hormone-refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med (Maywood) 2005; 230: 520-6.

2. Hammarsten P, Halin S, Wikstom P, Henriksson R, Rudolfsson SH, Bergh A. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006; 12: 7431-6.
3. Carlin S, Pugachev A, Sun X, et al. In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nucl Med Biol 2009; 36: 821-31.
4. Ma J, Waxman DJ. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 2009; 15: 578-88.
5. Kimura M, Rabbani Z, Mouraviev V, et al. Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology 2010; 76: 764 e14-20.
6. Kimura M, Rabbani Z, Mouraviev V, et al. Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology 2010; 61: 148-54.
7. Hagtvet E, Roe K, Olsen DR. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. Radiat Oncol 2011; 6: 135.
8. Baker LC, Boult JK, Walker-Samuel S, et al. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer 2012; 106: 1638-47.
9. Roe K, Mikalsen LT, van der Kogel AJ, et al. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiat Oncol 2012; 7: 75.

Renal Cell Carcinoma

1. van Wijngaarden J, de Rooij K, van Beek E, et al. Identification of differentially expressed genes in a renal cell carcinoma tumor model after endostatin-treatment. Lab Invest 2004; 84: 1472-83.
2. Murakami M, Zhao S, Zhao Y, et al. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 2012; 41: 1593-600.

Retinoblastoma

1. Boutrid H, Jockovich ME, Murray TG, et al. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci 2008; 49: 2799-805.
2. Boutrid H, Pina Y, Cebulla CM, et al. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci 2009; 50: 5537-43.

3. Pina Y, Houston SK, Murray TG, et al. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci 2010; 51: 6149-56.

Sarcoma

1. Laurent F, Benard P, Canal P, Soula G. Autoradiographic distribution of [14C]-labelled pimonidazole in rhabdomyosarcoma-bearing rats and pigmented mice. Cancer Chemother Pharmacol 1988; 22: 308-15.
2. Cobb LM, Nolan J, Butler SA. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues. Br J Cancer 1990; 62: 915-8.
3. Pogue BW, Paulsen KD, O'Hara JA, Wilmot CM, Swartz HM. Estimation of oxygen distribution in RIF-1 tumors by diffusion model- based interpretation of pimonidazole hypoxia and eppendorf measurements. Radiat Res 2001; 155: 15-25.
4. Cardenas-Navia LI, Yu D, Braun RD, Brizel DM, Secomb TW, Dewhirst MW. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res 2004; 64: 6010-7.
5. Davies Cd, Lundstrom LM, Frengen J, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 2004; 64: 547-53.
6. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004; 91: 1947-54.
7. Doege K, Heine S, Jensen I, Jelkmann W, Metzen E. Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact. Blood 2005; 106: 2311-7.
8. van der Schaft DWJ, Hillen F, Pauwels P, et al. Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia. Cancer Res 2005; 65: 11520-8.
9. Kleiter MM, Thrall DE, Malarkey DE, et al. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys 2006; 64: 592-602.
10. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006; 47: 989-98.
11. Busk M, Horsman MR, Jakobsen S, et al. Imaging Hypoxia in Xenografted and Murine Tumors With (18)F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, Po(2)-Polarography, and Fluorescence Microscopy. Int J Radiat Oncol Biol Phys 2008; 70: 1202-12.
12. Sersa G, Jarm T, Kotnik T, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-98.

13. Laifenfeld D, Gilchrist A, Drubin D, et al. The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma. Toxicol Sci 2010; 113: 254-66.
14. Dubois LJ, Lieuwes NG, Janssen MH, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011; 108: 14620-5.
15. Criswell KA, Cook JC, Morse D, et al. Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation. Toxicol Sci 2012; 128: 42-56.
16. D'Andrea FP, Safwat A, Burns JS, Kassem M, Horsman MR, Overgaard J. Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells. Int J Radiat Biol 2012; 88: 457-65.
17. Hansen AE, Kristensen AT, Jorgensen JT, et al. (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiat Oncol 2012; 7: 89.
18. Lemasson B, Christen T, Serduc R, et al. Evaluation of the Relationship between MR Estimates of Blood Oxygen Saturation and Hypoxia: Effect of an Antiangiogenic Treatment on a Gliosarcoma Model. Radiology 2012.

Squamous Cell Carcinoma

1. Bussink J, Kaanders JH, Rijken PF, Raleigh JA, Van der Kogel AJ. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res 2000; 153: 398-404.
2. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000; 48: 1529-38.
3. Petersen C, Eicheler W, Frommel A, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003; 79: 469-77.
4. Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 2004; 64: 6183-9.
5. Bhattacharya A, Toth K, Mazurchuk R, et al. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 2004; 10: 8005-17.
6. Nelson DW, Cao H, Zhu Y, et al. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. Cancer Res 2005; 65: 6151-8.
7. O'Donoghue J A, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using (18)F-fluoromisonidazole and (64)Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography:

Comparative study featuring microPET imaging, Po(2) probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493-502.
8. Solomon B, Binns D, Roselt P, et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 2005; 4: 1417-22.
9. van Herpen CM, Bussink J, van der Kogel AJ, et al. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1. Anticancer Res 2005; 25: 1015-10121.
10. Yaromina A, Holscher T, Eicheler W, et al. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma? Radiother Oncol 2005; 76: 206-12.
11. Troost EG, Laverman P, Kaanders JH, et al. Imaging hypoxia after oxygenation-modification: Comparing [(18)F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 2006.
12. Yaromina A, Zips D, Thames HD, et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiother Oncol 2006; 81: 122-9.
13. Matsumoto K, Szajek L, Krishna MC, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 2007; 30: 873-81.
14. Bayer C, Schilling D, Hoetzel J, et al. PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother Oncol 2008; 86: 361-8.
15. Busk M, Horsman MR, Jakobsen S, et al. Imaging Hypoxia in Xenografted and Murine Tumors With (18)F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, Po(2)-Polarography, and Fluorescence Microscopy. Int J Radiat Oncol Biol Phys 2008; 70: 1202-12.
16. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol 2008; 47: 1201-10.
17. Miyazaki Y, Hara A, Kato K, et al. The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. Int J Oncol 2008; 32: 145-51.
18. Troost EG, Laverman P, Philippens ME, et al. Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008; 35: 1803-11.
19. Bruechner K, Bergmann R, Santiago A, et al. Comparison of [(18)F]FDG uptake and distribution with hypoxia and proliferation in FaDu

human squamous cell carcinoma (hSCC) xenografts after single dose irradiation. Int J Radiat Biol 2009: 1-9.
20. Ellingsen C, Natvig I, Gaustad JV, Gulliksrud K, Egeland TA, Rofstad EK. Human cervical carcinoma xenograft models for studies of the physiological microenvironment of tumors. J Cancer Res Clin Oncol 2009.
21. Yaromina A, Quennet V, Zips D, et al. Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat Biol 2009; 85: 972-80.
22. Busk M, Munk OL, Jakobsen S, et al. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol 2010; 49: 922-33.
23. Santiago A, Eicheler W, Bussink J, et al. Effect of cetuximab and fractionated irradiation on tumour micro-environment. Radiother Oncol 2010; 97: 322-9.
24. Yaromina A, Thames H, Zhou X, et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010; 96: 116-22.
25. Maftei CA, Bayer C, Shi K, Astner ST, Vaupel P. Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: Evaluation using pattern recognition in microcirculatory supply units. Radiother Oncol 2011.
26. Maftei CA, Shi K, Bayer C, Astner ST, Vaupel P. Comparison of (immuno-)fluorescence data with serial [(1)F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers. Radiother Oncol 2011; 99: 412-7.
27. Vigneswaran N, Wu J, Song A, Annapragada A, Zacharias W. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol 2011; 90: 215-25.
28. Yaromina A, Kroeber T, Meinzer A, et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 2011; 80: 1205-13.
29. Zaleska K, Bruechner K, Baumann M, Zips D, Yaromina A. Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts. Radiother Oncol 2011.
30. Bayer C, Kielow A, Schilling D, et al. Monitoring PAI-1 and VEGF Levels in 6 Human Squamous Cell Carcinoma Xenografts During Fractionated Irradiation. Int J Radiat Oncol Biol Phys 2012; 84: e409-17.
31. Maftei CA, Bayer C, Shi K, Vaupel P. Intra- and intertumor heterogeneities in total, chronic, and acute hypoxia in xenografted squamous cell carcinomas. Detection and quantification using (immuno-)fluorescence techniques. Strahlenther Onkol 2012; 188: 606-15.

32. McCall KC, Humm JL, Bartlett R, Reese M, Carlin S. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) Pharmacokinetics in FaDu Xenograft Tumors and Correlation With Microscopic Markers of Hypoxia. Int J Radiat Oncol Biol Phys 2012; 84: e393-9.
33. Saito K, Matsumoto S, Devasahayam N, et al. Transient decrease in tumor oxygenation after intravenous administration of pyruvate. Magn Reson Med 2012; 67: 801-7.